pixantrone
information and resources from the National Cancer Institute
NCI Thesaurus | pixantrone
A synthetic noncardiotoxic aza-anthracenedione analogue. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. NCI Thesaurus | pixantrone
A synthetic noncardiotoxic aza-anthracenedione analogue. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.
|
|
|
|
news articles
Addition of Pixantrone to Rituxan(R) Therapy Significantly ... Nov 9, 2005
PR Newswire (press release), ...(CTI) (Nasdaq: CTIC; MTAX) presented results from a randomized controlled study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory patients ...
Addition of Pixantrone to Rituxan Therapy Significantly Prolongs ... Nov 9, 2005
PharmaLive.com (press release), ...(CTI) presented results from a randomized controlled study of Rituxan versus Rituxan plus pixantrone in 38 relapsed or refractory patients who had previously ...
Cell Therapeutics, Inc. Reports Third Quarter 2005 Financial ... Nov 14, 2005
PR Newswire (press release), Refocused Operations Leads to Significant Cost Reductions While Maintaining XYOTAX(TM) Registration and Pixantrone Development Timelines SEATTLE, Nov. ...
Cancer drug trial results touted Nov 10, 2005
Seattle Post Intelligencer In discussing a late-stage clinical trial involving 38 people and pixantrone, the company said the median time for patients who received the experimental ...
Cell Therapeutics, Inc. Reports Third Quarter 2005 Financial ... Nov 14, 2005
Yahoo! News (press release) The Company is focused on our regulatory filings for XYOTAX and advancing pixantrone to the phase III interim analysis, two important milestones for CTI in 2006 ...
Women to be focus of tests on cancer drug Nov 15, 2005
Seattle Times, ...it has cut its US work force by almost two-thirds to 107 this year — and by refocusing its business on Xyotax and another cancer treatment, pixantrone. ...
Cell hits treatment goals, but stock is sold Nov 11, 2005
Seattle Times, Cell Therapeutics said it hit its treatment goals in a trial of pixantrone in patients with relapsed non-Hodgkin's lymphoma, but investors sold off the Seattle ...
|
|
